The correlation between serum Apelin, IGF-2 and GLUT1 levels with tumor proliferation and recurrence in children with hemangioma

doi:10.11958/20242337

Abstract

Abstract:

Objective To investigate the relationship between serum endogenous ligand (Apelin), insulin-like growth factor-2 (IGF-2) glucose transporter 1 (GLUT1) and tumor hyperplasia and recurrence after withdrawal propranolol in infantile hemangioma (IH) children. Methods A total of 126 IH patients were selected and divided into the proliferative phase group (74 cases) and the involuting phase group (52 cases) based on the pathological results. Meanwhile, 56 patients with vascular malformations were selected as the vascular malformation group. Enzyme-linked immunosorbent assay (ELISA) was used to detect the serum levels of Apelin, IGF-2 and GLUT1 on the day after admission. All IH patients were treated with propranolol for 3 months. According to the follow-up results, IH patients were divided into the recurrence group (43 cases) and the non-recurrence group (83 cases). Serum levels of Apelin, IGF-2 and GLUT1 were compared between different groups of patients. Multivariate Logistic regression analysis was used to analyze risk factors for recurrence after propranolol discontinuation in IH patients. The prediction value of serum Apelin, IGF-2 and GLUT1 levels for recurrence after propranolol discontinuation in IH patients was analyzed by receiver operating characteristic curve (ROC). Results Compared with the vascular malformation group, serum levels of Apelin, IGF-2 and GLUT1were increased in the IH group (P<0.05). Compared with the degenerative group, serum levels of Apelin, IGF-2 and GLUT1 were increased in the proliferative group (P<0.05). Serum levels of Apelin, IGF-2 and GLUT1 were significantly higher in the recurrence group than those in the non-recurrence group (P<0.05). The increased Apelin, IGF-2 and GLUT1, and hemangioma grade I -II after treatment were independent risk factors for recurrence after withdrawal of propranolol in children with IH (P<0.05). The area under the curve (AUC) of Apelin, IGF-2 and GLUT1 combined predicted IH recurrence was better than that of simple prediction (P<0.05). Conclusion The increased serum levels of Apelin, IGF-2 and GLUT1 in IH patients can be used as serum indicators to predict tumor hyperplasia and recurrence after propranolol withdrawal in patients.

Key words: hemangioma, Apelin, insulin-like growth factor Ⅱ, glucose transporter type 1, propranolol, recurrence

CLC Number:

R732.2

Figures/Tables 7

References 25

[1]	JUNG H L. Update on infantile hemangioma[J]. Clinical and Experimental Pediatrics, 2021, 64(11):559. doi:10.3345/cep.2020.02061.
[2]	钱国庆, 蔡昶, 李丹, 等. 血管瘤患儿血清粒细胞-巨噬细胞集落刺激因子及转录激活因子3水平与瘤体增生的相关性[J]. 中国小儿血液与肿瘤杂志, 2024, 29(1):27-31.
	QIAN G Q, CAI C, LI D, et al. Correlation between serum granulocyte macrophage colony stimulating factor and transcriptional activating factor 3 levels and tumor proliferation in children with vascular tumor[J]. J China Pediatr Blood Cancer, 2024, 29(1):27-31. doi:10.3969/j.issn.1673-5323.2024.01.005.
[3]	ALAKEEL A, ALSALMAN H, ALOTAIBI G, et al. Propranolol-induced hyperkalemia in infantile hemangioma patients:how serious is it?[J]. J Family Med Prim Care, 2022, 11(11):6944-6948. doi:10.4103/jfmpc.jfmpc_658_22.
[4]	郭彦, 张凯, 范戌辉, 等. 血清miR-199a-5p、miR-378a-3p水平与婴幼儿增殖期面部血管瘤普萘洛尔停药后复发的关系[J]. 口腔疾病防治, 2022, 30(2):97-102.
	GUO Y, ZHANG K, FAN X H, et al. Relationship between serum miR-199a-5p and miR-378a-3p levels and recurrence of infants with proliferative facial hemangioma after propranolol withdrawal[J]. Journal of Prevention and Treatment for Stomatological Diseases, 2022, 30(2):97-102. doi:10.12016/j.issn.2096-1456.2022.02.004.
[5]	URIBESALGO I, HOFFMANN D, ZHANG Y, et al. Apelin inhibition prevents resistance and metastasis associated with anti-angiogenic therapy[J]. EMBO Mol Med, 2019, 11(8):e9266. doi:10.15252/emmm.201809266.
[6]	CHEN Q, ZHANG Y, NI S, et al. Serum apelin as a potential biomarker for infantile hemangiomas[J]. Pediatr Blood Cancer, 2024, 71(7):e30989. doi:10.1002/pbc.30989.
[7]	PICARD A, BOSCOLO E, KHAN Z A, et al. IGF-2 and FLT-1/VEGF-R1 mRNA levels reveal distinctions and similarities between congenital and common infantile hemangioma[J]. Pediatr Res, 2008, 63(3):263-267. doi:10.1203/PDR.0b013e318163a243.
[8]	AYDIN KÖKER S, KÖMÜROĞLU A U, KÖKSOY A Y, et al. Evaluation of GLUT1,IGF-2,VEGF,FGF 1,and angiopoietin 2 in infantile hemangioma[J]. Arch Pediatr, 2021, 28(4):296-300. doi:10.1016/j.arcped.2021.02.009.
[9]	中华医学会整形外科分会血管瘤脉管畸形学组. 血管瘤与脉管畸形诊疗指南(2024版)[J]. 组织工程与重建外科杂志, 2024, 20(1):1-50.
	Hemangioma vascular teratology Group, Plastic Surgery Society of Chinese Medical Association. Guidelines for diagnosis and treatment of hemangiomas and vascular malformations(2024 edition)[J]. Journal of Tissue Engineering and Reconstructive Surgery, 2024, 20(1):1-50. doi:10.3969/j.issn.1673-0364.2024.01.001.
[10]	CHANG L, GU Y, YU Z, et al. When to stop propranolol for infantile hemangioma[J]. Sci Rep, 2017,7:43292. doi:10.1038/srep43292.
[11]	ACHAUER B M, CHANG C J, VANDER KAM V M. Management of hemangioma of infancy: review of 245 patients[J]. Plast Reconstr Surg, 1997, 99(5):1301-1308. doi:10.1097/00006534-199704001-00014.
[12]	SUN Y, QIU F, HU C, et al. Hemangioma endothelial cells and hemangioma stem cells in infantile hemangioma[J]. Ann Plast Surg, 2022, 88(2):244-249. doi:10.1097/SAP.0000000000002835.
[13]	KROWCHUK D P, FRIEDEN I J, MANCINI A J, et al. Clinical practice guideline for the management of infantile hemangiomas[J]. Pediatrics, 2019, 143(1):e20183475. doi:10.1542/peds.2018-3475.
[14]	KOWALSKA M, DĘBEK W, MATUSZCZAK E. Infantile hemangiomas:an update on pathogenesis and treatment[J]. J Clin Med, 2021, 10(20):4631. doi:10.3390/jcm10204631.
[15]	PENSABENE M, DI PACE M R, BALDANZA F, et al. Quality of life improving after propranolol treatment in patients with infantile hemangiomas[J]. Ital J Pediatr, 2022, 48(1):140. doi:10.1186/s13052-022-01334-2.
[16]	YANG H, HU D L, SHU Q, et al. Efficacy and adverse effects of oral propranolol in infantile hemangioma: a meta-analysis of comparative studies[J]. World J Pediatr, 2019, 15(6):546-558. doi:10.1007/s12519-019-00285-9.
[17]	HELKER C S, EBERLEIN J, WILHELM K, et al. Apelin signaling drives vascular endothelial cells toward a pro-angiogenic state[J]. Elife, 2020,9:e55589. doi:10.7554/eLife.55589.
[18]	梁燕茹, 郑瑜, 李倩. 子宫内膜癌患者术前血清apo AI和Apelin水平检测对预测淋巴脉管间隙浸润风险的价值研究[J]. 现代检验医学杂志, 2023, 38(5):53-57,85.
	LIANG Y R, ZHENG Y, LI Q. Value of preoperative serum apo AI and Apelin levels in predicting the risk of lymph node vascular space infiltration in patients with endometrial cancer[J]. J Mod Lab Med, 2023, 38(5):53-57,85. doi:10.3969/j.issn.1671-7414.2023.05.010.
[19]	CHEN Q, YING H, YU Z, et al. Apelin receptor can act as a specific marker and promising therapeutic target for infantile hemangioma[J]. J Invest Dermatol, 2023, 143(4):566-577.e12. doi:10.1016/j.jid.2022.09.657.
[20]	MIN S K, KIM M, PARK J B. Insulin-like growth factor 2-enhanced osteogenic differentiation of stem cell spheroids by regulation of Runx2 and Col1 expression[J]. Exp Ther Med, 2021, 21(4):383. doi:10.3892/etm.2021.9814.
[21]	KLEIMAN A, KEATS E C, CHAN N G, et al. Elevated IGF2 prevents leptin induction and terminal adipocyte differentiation in hemangioma stem cells[J]. Exp Mol Pathol, 2013, 94(1):126-136. doi:10.1016/j.yexmp.2012.09.023.
[22]	ZHANG K, WANG F, HUANG J, et al. Insulin-like growth factor 2 promotes the adipogenesis of hemangioma-derived stem cells[J]. Exp Ther Med, 2019, 17(3):1663-1669. doi:10.3892/etm.2018.7132.
[23]	HUANG L, BISCHOFF J. Isolation of stem cells,endothelial cells and pericytes from human infantile hemangioma[J]. Bio Protoc, 2020, 10(2):e3487. doi:10.21769/BioProtoc.3487.
[24]	杨开颖, 周江元, 龚雪, 等. 糖酵解通路关键酶在婴幼儿血管瘤中的表达及其作用[J]. 中华小儿外科杂志, 2022, 43(11):1007-1012.
	YANG K Y, ZHOU J Y, GONG X, et al. Expression profiles and roles of key glycolytic enzymes in infantile hemangioma[J]. Chin J Pediatr Surg, 2022, 43(11):1007-1012. doi:10.3760/cma.j.cn421158-20210513-00237.
[25]	HUANG L, NAKAYAMA H, KLAGSBRUN M, et al. Glucose transporter 1-positive endothelial cells in infantile hemangioma exhibit features of facultative stem cells[J]. Stem Cells, 2015, 33(1):133-145. doi:10.1002/stem.1841.

组别	n	Apelin/（ng/L）	IGF-2/（μg/L）	GLUT1/（μg/L）
血管畸形组	56	103.64±10.73	6.38±0.65	7.36±0.78
IH组	126	126.16±12.78	7.78±0.78	8.70±0.89
t		11.503^＊＊	11.737^＊＊	9.726^＊＊

组别	n	Apelin/（ng/L）	IGF-2/（μg/L）	GLUT1/（μg/L）
血管畸形组	56	103.64±10.73	6.38±0.65	7.36±0.78
IH组	126	126.16±12.78	7.78±0.78	8.70±0.89
t		11.503^＊＊	11.737^＊＊	9.726^＊＊

组别	n	Apelin/（ng/L）	IGF-2/（μg/L）	GLUT1/（μg/L）
退化期组	52	118.39±12.49	7.27±0.74	8.04±0.84
增生期组	74	131.62±13.85	8.13±0.85	9.16±0.98
t		5.494^＊＊	5.892^＊＊	6.691^＊＊

组别	n	Apelin/（ng/L）	IGF-2/（μg/L）	GLUT1/（μg/L）
退化期组	52	118.39±12.49	7.27±0.74	8.04±0.84
增生期组	74	131.62±13.85	8.13±0.85	9.16±0.98
t		5.494^＊＊	5.892^＊＊	6.691^＊＊

组别		n	年龄/月		性别
组别		n	年龄/月		男		女
未复发组		83	5.13±0.52		47（56.63）		36（43.37）
复发组		43	5.19±0.53		26（60.47）		17（39.53）
χ²或t			0.610		0.171
组别	肿瘤面积					肿瘤分布模式
组别	≥5 cm²			<5 cm²		节段性		非节段性
未复发组	41（49.40）			42（50.60）		45（54.22）		38（45.78）
复发组	24（55.81）			19（44.19）		26（60.47）		17（39.53）
χ²	0.467					0.450
组别	治疗时间					治疗后分级
组别	≥6个月			<6个月		Ⅰ—Ⅱ级		Ⅲ—Ⅳ级
未复发组	49（59.04）			34（40.96）		28（33.73）		55（66.27）
复发组	18（41.86）			25（58.14）		29（67.44）		14（32.56）
χ²	3.356					12.991^＊＊